Dec. 6 at 9:04 PM
Commercial-stage oncology focused M&A has been active with 6 acquisitions YTD (still 3.5 weeks left), 4 in FY24 & 5 in FY23. They are averaging more than 1 per quarter (right side of the attachment).
In May 24 MACK was technically an exit but via CVR payout so after Ono acquired DCPH in April via traditional M&A, there was a 10 month dry spell.
Our investment club believes there will be an acquisition before JP Morgan, most likely SNDX by INCY. We're speculating so of course we c/b wrong.
The left side of the attachment lists all available & reasonably credible candidates.
$KPTI is a textbook example of why bios should exit after FDA approval. Of course KPTI may work out with 2 major reads next year (they know it works in endometrial). Because they've waited this long we believe there's no chance they sell but again o/c we c/b wrong. Same with
$FENC but at least they tried
Our other most likely candidates include (in order)
$URGN &
$ZYME
$DCTH by March (3 years since the P/E financing)
